Irbesartan Drug Asset Due Diligence Report 2026

This Irbesartan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

205

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Irbesartan can convert its Small molecule drug profile and AT1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Irbesartan (query alias: irbesartan)
Modality / target	Small molecule drug; AT1R; AT1R antagonists
Highest global status	Approved
Originator	Sanofi
Active developers	Zentiva ks, Sanofi Winthrop Industrie SA, KRKA dd

The MCP disease footprint includes Diabetes Mellitus, Type 2, Hypertension, Type 2 diabetes mellitus with established diabetic nephropathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07547878	Phase 4	Not yet recruiting	64	On-study retention rate at 6 months
CTR20261810	Phase 1	进行中（招募完成）	32	Not disclosed
ChiCTR2500108026	Not Applicable	Pending	40	Primary endpoint

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: irbesartan-related hypotension = Eleven episodes of irbesartan-related hypotension were recorded, leading to a downtitration in 4 patients ; Adverse Event: irbesartan-related hypotension = Eleven episodes of irbesartan-related hypotension were recorded, leading to a downtitration in 4 patients

A Five‐Year Prospective, Randomized, Open‐Label Study of Standard‐Dose Versus Low‐Dose Prolonged‐Release Tacrolimus With or Without Angiotensin‐Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation

Phase 3; n=281; evaluation: Positive. Reported fields: Graft Survival = 89.7 % ; Graft Survival = 97.1 % ; Graft Survival = 94.4 %

The Efficacy and Tolerability of Irbesartan/Amlodipine Combination Therapy in Patients With Essential Hypertension Whose Blood Pressure Were not Controlled by Irbesartan Monotherapy

Phase 3; n=428; evaluation: Positive. Reported fields: SBP = -7.19 mmHg ( 15.37); SBP = -13.3 mmHg ( 12.47); SBP = -21.47 mmHg ( 12.78)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Irbesartan addresses Diabetes Mellitus, Type 2, Hypertension, Type 2 diabetes mellitus with established diabetic nephropathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
1997-01-01	PLAVIX® was codeveloped and is jointly marketed by BMS and sanofi-aventis.	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Oral solid medicinal composition containing irbesartan and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Medicinal composition containing irbesartan and hydrochlorothiazide and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Method for analyzing and regulating crystal form transformation in irbesartan nano suspension preparation process”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO